兽医再生医学市场－全球产业规模、份额、趋势、机会和预测：按动物类型、产品、应用、最终用途、地区和竞争格局划分，2021-2031年

全球兽医再生医学市场预计将大幅成长，从 2025 年的 3.2172 亿美元成长到 2031 年的 5.9366 亿美元，复合年增长率为 10.75%。

该市场专注于利用干细胞疗法、富血小板血浆（PRP）和组织工程等生物疗法来修復或替换受损的动物组织。推动这一市场扩张的关键因素包括骨关节炎等慢性整形外科疾病的日益普遍以及宠物人性化的趋势。这促使饲主寻求更先进的医疗干预措施，而对动物医疗保健的大量投资也支持了这项需求。根据美国宠物用品协会（APPA）预测，到2024年，美国宠物产业的总支出预计将达到1,506亿美元，这意味着兽医服务和医疗保健领域的资本投入将大幅成长。

阻碍市场成长的主要障碍之一是研发和实施这些特殊治疗方法的高成本。生物材料的采集和加工成本往往导致价格高昂，限制了许多宠物饲主的取得途径。此外，缺乏全球统一的法规结构也为製造商带来了合规方面的复杂性。这些监管方面的挑战可能会延缓主要国际地区新型再生医学产品的核准和商业化进程，进一步阻碍市场扩张。

市场驱动因素

宠物人性化的趋势日益增强，宠物饲养率不断攀升，这成为全球兽医再生医学市场发展的重要驱动力。随着饲主越来越将伴侣动物视为家庭成员，他们也越来越愿意投资能够延长寿命、缓解慢性疼痛的治疗方法。这种情感纽带推动了对干细胞和富血小板血浆疗法的需求，尤其针对患有老龄化退化性整形外科疾病的老年犬。美国兽医协会的报告显示，到2025年10月，美国犬隻数量将增加至8,730万隻，这充分体现了这个市场的巨大潜力。各公司正积极筹集资金，以可扩展的解决方案满足这项需求。例如，Gallant Therapeutics公司于2025年6月完成了1,800万美元的B轮资金筹措，用于其即用型干细胞产品的商业化。

此外，宠物医疗保健成本的不断上涨和宠物保险的日益普及，正在弥合临床可及性和经济负担之间的差距，从而加速市场成长。虽然高昂的费用历来阻碍再生医学的广泛应用，但宠物保险的普及正在消除这些经济障碍。随着保险范围扩大到復健和再生医学手术，兽医现在能够在治疗早期就开立这些有效的治疗方法。这种向财务保障的转变势头强劲，北美宠物健康保险协会 (NAPHIA) 报告称，到 2025 年 4 月，北美投保宠物的总数将达到 703 万隻，同比增长 12.2%。

市场挑战

再生医学研发和应用的高昂成本是其广泛应用的主要障碍。儘管人们对改善动物医疗保健的需求日益增长，但干细胞疗法和组织工程的高昂费用使许多宠物饲主难以负担。由于大多数兽医费用需要自付而非透过全面的保险计划支付，这些特殊治疗的经济负担往往迫使宠物主人选择传统的、费用较低的治疗方法，例如治疗骨关节炎等疾病。这种价格敏感度将客户群限制在富裕的小众群中，阻碍了市场成熟所需的规模化发展。

这些经济限制因素因近期该产业消费者支出的变化而进一步凸显，这与整个产业资本成长的整体趋势背道而驰。根据美国兽医协会（AVMA）预测，2024年兽医总支出将年减4%。儘管消费者对高端医疗服务的需求依然旺盛，但该行业的这一萎缩表明实际购买力正在下降。因此，製造商难以实现规模经济以降低高昂的治疗成本，从而形成恶性循环，阻碍了其在关键地区的市场渗透。

市场趋势

该行业正积极从以患者为中心的内部製备模式转向生产可扩展的、具有标准化药物功能的同种异体「现成」疗法。这项转变将使企业能够克服与单例治疗相关的物流和财务瓶颈，并生产出稳定、受监管的批次产品以供大规模分销。为了响应这一向工业化规模再生医学生产的趋势，生物技术公司正拨出大量资金用于建造专门的生产基础设施，以满足未来的商业需求。例如，根据《波兰洞察》（Polish Insight）2025年9月报道，BioCeltics计划透过股票上市筹集资金，用于建造一座新的大型干细胞生产设施，该营运成本5000万波币。

市场扩张的进一步驱动力在于研究方向的多元化，从犬类整形外科的常规研究转向其他伴侣动物（尤其是猫科动物）复杂慢性疾病的专科治疗。这一趋势旨在解决猫科动物治疗选择不足这一长期难题，将研发资源集中在肾衰竭和心肌病等高发病（这些疾病需要个体化的生物干预，而非跨物种的适应性治疗）。这种物种特异性方法的推进势头在学术界和产业界研究提案的激增中可见一斑。 2024年12月，莫里斯动物基金会报告称，已收到50多份专门用于推进猫科动物健康科学的津贴提案，其中包括慢性肾臟病和心臟病的研究。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球兽医再生医学市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 动物种类（小型动物、大型动物）
  • 副产品（干细胞、其他）
  • 按应用领域（整形外科、创伤/创伤护理、其他）
  • 依用途（动物医院/诊所、动物研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美兽医再生医学市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲兽医再生医学市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区兽医再生医学市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲兽医再生医学市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲兽医再生医学市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球兽医再生医学市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Boehringer Ingelheim International GmbH
• Zoetis Inc.
• Dechra Pharmaceuticals PLC
• Integra LifeSciences Incorporation
• Vetherapy
• VetStem, Inc.
• Ardent Animal Health, LLC
• Enso Discoveries, LLC
• Animal Cell Therapies, Inc.
• Vetbiologics LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Regenerative Medicine Market is projected to experience substantial growth, expanding from USD 321.72 Million in 2025 to USD 593.66 Million by 2031 at a CAGR of 10.75%. This market focuses on utilizing biological therapies, such as stem cell treatments, platelet-rich plasma, and tissue engineering, to repair or replace damaged animal tissues. Key drivers fueling this expansion include the rising prevalence of chronic orthopedic conditions like osteoarthritis and the growing trend of pet humanization, which motivates owners to seek advanced medical interventions. This demand is underpinned by significant financial dedication to animal healthcare; the American Pet Products Association projected that total U.S. pet industry expenditures would reach 150.6 billion dollars in 2024, signaling a major increase in capital allocation toward veterinary services and wellness.

One significant obstacle hindering market growth is the high cost associated with developing and administering these specialized therapies. The expenses involved in harvesting and processing biological materials often result in prohibitive prices that limit accessibility for a large portion of pet owners. Furthermore, the absence of globally harmonized regulatory frameworks introduces compliance complexities for manufacturers. These regulatory challenges can delay the approval and commercialization of new regenerative products in key international regions, further impeding market expansion.

Market Driver

The increasing trend of pet humanization and rising adoption rates act as fundamental catalysts for the Global Veterinary Regenerative Medicine Market. As owners increasingly view their companion animals as integral family members, they are more willing to invest in advanced treatments that extend lifespan and alleviate chronic pain. This emotional bond drives the demand for stem cell and platelet-rich plasma therapies, particularly for aging dogs suffering from degenerative orthopedic conditions. The magnitude of this opportunity is underscored by the American Veterinary Medical Association, which noted that the U.S. dog population grew to 87.3 million in October 2025. To meet this demand with scalable solutions, companies are securing significant capital, as demonstrated when Gallant Therapeutics closed an 18 million dollar Series B financing round in June 2025 to commercialize off-the-shelf stem cell products.

Additionally, growing pet healthcare expenditure and the increasing penetration of pet insurance are accelerating market expansion by bridging the gap between clinical availability and affordability. While high costs have historically restricted the reach of regenerative therapies, the widespread adoption of pet insurance is dismantling these financial barriers. As insurance coverage expands to include rehabilitative and regenerative procedures, veterinarians are empowered to prescribe these effective treatments earlier in the care process. This shift toward financial protection is robust; the North American Pet Health Insurance Association reported that the total number of insured pets in North America reached 7.03 million in April 2025, representing a 12.2 percent increase from the previous year.

Market Challenge

The high costs associated with developing and administering regenerative therapies present a significant barrier to their widespread adoption. Although the demand for improved animal healthcare is rising, the substantial expense required for stem cell treatments and tissue engineering places these options out of reach for a vast demographic of pet owners. Since the majority of veterinary costs are paid directly out-of-pocket rather than through comprehensive insurance plans, the economic burden of such specialized care often forces clients to choose conventional, less expensive management strategies for conditions like osteoarthritis. This price sensitivity limits the customer base to a niche segment of affluent clients, thereby stalling the volume growth necessary for the market to mature.

This financial constraint is further highlighted by recent shifts in consumer expenditure within the sector, which contradict the broader trend of increased industry capitalization. According to the American Veterinary Medical Association, overall veterinary spending decreased by 4% in 2024 compared to the previous year. This contraction in specific veterinary allocation indicates that despite the emotional drive for premium care, actual purchasing power is tightening. Consequently, manufacturers face difficulties in achieving the economies of scale needed to reduce prohibitive treatment prices, creating a cycle that restricts market penetration in key regions.

Market Trends

The industry is aggressively pivoting from autologous, patient-side processing toward the manufacturing of scalable, allogeneic "off-the-shelf" therapies that operate like standard pharmaceuticals. This transition allows companies to overcome the logistical and financial bottlenecks of single-patient treatments by producing consistent, regulatorily compliant batches for mass distribution. Reflecting this move toward industrial-scale regenerative manufacturing, biotechnology firms are securing significant capital to build specialized production infrastructure to meet future commercial demand. For instance, Poland Insight reported in September 2025 that Bioceltix is planning a share issue to finance the construction of a new large-scale stem cell production facility with a total project value of 50 million Polish Zloty.

Market expansion is further driven by a diversification of research beyond general canine orthopedics into specialized treatments for complex chronic conditions in other companion species, particularly felines. This trend addresses the historical lack of therapeutic options for cats by directing R&D resources toward high-prevalence ailments such as renal failure and cardiomyopathy, which require tailored biological interventions rather than cross-species adaptations. The momentum behind this species-targeted approach is evident in the surging volume of academic and industrial research proposals; the Morris Animal Foundation reported in December 2024 that it received more than 50 grant proposals specifically dedicated to advancing feline health science, including studies on chronic kidney disease and heart disease.

Key Market Players

• Boehringer Ingelheim International GmbH
• Zoetis Inc.
• Dechra Pharmaceuticals PLC
• Integra LifeSciences Incorporation
• Vetherapy
• VetStem, Inc.
• Ardent Animal Health, LLC
• Enso Discoveries, LLC
• Animal Cell Therapies, Inc.
• Vetbiologics LLC

Report Scope

In this report, the Global Veterinary Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Regenerative Medicine Market, By Animal Type

• Small Animals
• Large Animals

Veterinary Regenerative Medicine Market, By Product

• Stem Cells
• Others

Veterinary Regenerative Medicine Market, By Application

• Orthopedics
• Trauma/Wound Care
• Others

Veterinary Regenerative Medicine Market, By End-Use

• Veterinary Hospitals/Clinics
• Veterinary Research Institutes

Veterinary Regenerative Medicine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Regenerative Medicine Market.

Available Customizations:

Global Veterinary Regenerative Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Regenerative Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Small Animals, Large Animals)
  • 5.2.2. By Product (Stem Cells, Others)
  • 5.2.3. By Application (Orthopedics, Trauma/Wound Care, Others)
  • 5.2.4. By End-Use (Veterinary Hospitals/Clinics, Veterinary Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Regenerative Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By End-Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Regenerative Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-Use
  • 6.3.2. Canada Veterinary Regenerative Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-Use
  • 6.3.3. Mexico Veterinary Regenerative Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-Use

7. Europe Veterinary Regenerative Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By End-Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Regenerative Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-Use
  • 7.3.2. France Veterinary Regenerative Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-Use
  • 7.3.3. United Kingdom Veterinary Regenerative Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-Use
  • 7.3.4. Italy Veterinary Regenerative Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-Use
  • 7.3.5. Spain Veterinary Regenerative Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-Use

8. Asia Pacific Veterinary Regenerative Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By End-Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Regenerative Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-Use
  • 8.3.2. India Veterinary Regenerative Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-Use
  • 8.3.3. Japan Veterinary Regenerative Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-Use
  • 8.3.4. South Korea Veterinary Regenerative Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-Use
  • 8.3.5. Australia Veterinary Regenerative Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-Use

9. Middle East & Africa Veterinary Regenerative Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By End-Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Regenerative Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-Use
  • 9.3.2. UAE Veterinary Regenerative Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-Use
  • 9.3.3. South Africa Veterinary Regenerative Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-Use

10. South America Veterinary Regenerative Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By End-Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Regenerative Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-Use
  • 10.3.2. Colombia Veterinary Regenerative Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-Use
  • 10.3.3. Argentina Veterinary Regenerative Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Regenerative Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Zoetis Inc.
• 15.3. Dechra Pharmaceuticals PLC
• 15.4. Integra LifeSciences Incorporation
• 15.5. Vetherapy
• 15.6. VetStem, Inc.
• 15.7. Ardent Animal Health, LLC
• 15.8. Enso Discoveries, LLC
• 15.9. Animal Cell Therapies, Inc.
• 15.10. Vetbiologics LLC

16. Strategic Recommendations

17. About Us & Disclaimer